In July, Carmat announced the enrolment of the 10th and final patient included in the first leg of its EU pivotal study investigating the surgical implantation of the Carmat total artificial heart (TAH) in patients suffering from end-stage biventricular heart failure (HF). Following the successful surgeries, the company expects to enrol an additional 10 patients in the second cohort by the year end. According to Carmat, data from all 20 patients should be sufficient to obtain CE marking for t
26 Oct 2018
Carmat - First half of CE mark-enabling trial fully enrolled
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Carmat - First half of CE mark-enabling trial fully enrolled
Carmat SA (ALCAR:PAR) | 0 0 0.7% | Mkt Cap: 195.7m
- Published:
26 Oct 2018 -
Author:
Maxim Jacobs -
Pages:
6
In July, Carmat announced the enrolment of the 10th and final patient included in the first leg of its EU pivotal study investigating the surgical implantation of the Carmat total artificial heart (TAH) in patients suffering from end-stage biventricular heart failure (HF). Following the successful surgeries, the company expects to enrol an additional 10 patients in the second cohort by the year end. According to Carmat, data from all 20 patients should be sufficient to obtain CE marking for t